Neurocrine Biosciences | NBIX - Fremdkapital





Fremdkapital Veränderung Datum
AbbVie USD 58.94B 4.03B 2025-12
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
ALKERMES USD 1.48B 1.2B 2026-03
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
Amgen USD 51.89B 1.88B 2026-03
Biogen USD 6.29B 1.7M 2026-03
BioMarin Pharmaceutical USD 1.43B 833.11M 2026-03
Cytokinetics USD 247.21M 868.77M 2026-03
Enanta Pharmaceuticals USD 0 0 2024-12
Gilead Sciences USD 20.86B 1.27B 2026-03
Halozyme Therapeutics USD 1.94B 206.73M 2026-03
Incyte USD 29.41M 785K 2026-03
Ionis Pharmaceuticals USD 1.91B 9M 2026-03
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
Pfizer USD 60.57B 1.08B 2026-03
Prothena USD 0 0 2024-12
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Repligen USD 546.58M 4.37M 2026-03
Rigel Pharmaceuticals USD 0 0 2024-09
Sarepta Therapeutics USD 838.16M 9.19M 2026-03
Teva Pharmaceutical Industries USD 14.02B 971M 2026-03
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12
Xoma USD 94.38M 7.82M 2025-09